7EDF85E0-24E3-43B6-8C00-BBA39235266E
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2.759526938239159
- age_years
- 41
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.485
- UV_RESPONSE_DN+0.428
- NOTCH_SIGNALING+0.385
- TGF_BETA_SIGNALING+0.361
- MITOTIC_SPINDLE+0.312
- ESTROGEN_RESPONSE_EARLY+0.310
- PROTEIN_SECRETION+0.276
- ANDROGEN_RESPONSE+0.270
- TNFA_SIGNALING_VIA_NFKB+0.255
- MTORC1_SIGNALING+0.246
Top 10 suppressed
- INTERFERON_GAMMA_RESPONSE-0.163
- INTERFERON_ALPHA_RESPONSE-0.156
- DNA_REPAIR-0.151
- MYOGENESIS-0.106
- IL6_JAK_STAT3_SIGNALING-0.078
- XENOBIOTIC_METABOLISM-0.015
- KRAS_SIGNALING_DN-0.013
- P53_PATHWAY-0.005
- ANGIOGENESIS+0.002
- SPERMATOGENESIS+0.005
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 45B7816C-0A67-441C-8E80-656EAF2AD940 | — | — | 0.863 |
| 2 | TCGA-77-7338-01A-11R-2045-07 | — | cohortSQ2 | 0.810 |
| 3 | CF764E50-B0F9-44DE-8B48-F8F5A8920240 | — | — | 0.796 |
| 4 | 106E2A94-0366-4D5E-894F-41117C78E18C | — | — | 0.789 |
| 5 | SRR934850 | — | — | 0.782 |
| 6 | SRR1313150 | — | E | 0.776 |
| 7 | 61C38CFD-F57F-48D2-9FC7-81776647CF0E | — | — | 0.776 |
| 8 | 5282B52E-8573-4FC0-9BED-420AE3D2B096 | — | — | 0.772 |
| 9 | 8D30F824-25B9-43DB-BD39-2C9C790509DD | — | — | 0.761 |
| 10 | C138638F-C6CB-439B-BFF0-CF097E0B421E | — | — | 0.760 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.485 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.428 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.385 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.361 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.312 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.276 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.270 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.255 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.246 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.238 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.236 | Inavolisib | — uncovered |
| APOPTOSIS | 0.224 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.219 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.207 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.196 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.190 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.189 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |